MedTrace Logo

Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma

NCT00052624 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-05-15

No results posted yet for this study

Summary

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for glioblastoma multiforme and anaplastic astrocytoma.

PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy in treating children who have progressive or recurrent glioblastoma multiforme or anaplastic astrocytoma

Conditions

Interventions

BIOLOGICAL

transferrin-CRM107

Sponsors & Collaborators

  • Xenova Biomedix

    lead INDUSTRY

Principal Investigators

  • Patrick Rossi, MD · Xenova Biomedix

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00052624 on ClinicalTrials.gov